Stereotactic body radiation therapy or SBRT (sometimes referred to as Cyberknife or SHARP) has had excellent 7-year outcomes in an update of the consortium study, including data from 10 single-institution trials and two multi-institutional trials. Get the details HERE.
Dilemma: Intermediate Risk Prostate Cancer and Active Surveillance
Men who are initially diagnosed with intermediate-risk prostate cancer may or may not be good candidates for Active Surveillance. This excellent article begins to provide a basis for making that determination. You can read the article by clicking HERE.
ASTRO, ASCO, and AUA Strongly Endorse Shortened Course Of IMRT For Primary Therapy
Moderately hypofractionated IMRT (radiation therapy delivered in 20 to 26 treatments instead of the conventional 40-44 treatments) has received strong endorsement from all of the major US organizations of physicians who treat prostate cancer. Read more about this significant new guideline here.
Can Hormone Therapy Make Prostate Cancer Worse?
Scientists at Cedars-Sinai have discovered how prostate cancer can sometimes withstand and outwit a standard hormone therapy, causing the cancer to spread. Their findings also point to a simple blood test that may help doctors predict when this type of hormone therapy resistance will occur. Learn more about these interesting findings by clicking HERE.